RAPP Stock Forecast & Price Target

Rapport Therapeutics is attractive because RAP-219 offers a differentiated, non-dopaminergic mechanism that directly targets TARPγ8-associated AMPA signaling in brain regions implicated in mania, potentially avoiding the sedation, weight gain, EPS, and orthostatic burdens that limit existing therapies. Its bipolar mania program is designed to produce a clean signal, with a 250-patient Phase 2 study powered at 80% to detect a 4-point placebo-adjusted YMRS improvement, while even a 3- to 4-point benefit could still support advancement if tolerability remains strong. The investment case is further strengthened by RAP-219’s ~22-day half-life, the broader “pipeline in a product” opportunity across epilepsy and mania, and projected peak sales of $3.3B to $3.7B.

Rapport Therapeutics is burdened by a highly uncertain, development-stage profile, with value tied almost entirely to RAP-219 and preclinical discovery assets that have no approved products or recurring revenue. Although bipolar mania and epilepsy represent large unmet needs, the company still faces significant clinical, regulatory, commercial, and manufacturing risk, and even its own analysis implies a 30% to 40% refractory patient pool does not guarantee adoption if efficacy or tolerability disappoints. The outlook is further weakened by dependence on additional funding, third-party CDMOs, and competition from more advanced therapies, making the path to durable value creation fragile despite the long-duration DCF framework through 2045.